Alaunos Therapeutics (TCRT) Non-Current Deffered Revenue (2009 - 2018)

Alaunos Therapeutics has reported Non-Current Deffered Revenue for 10 years, with the latest figure at $4000.0 in Q4 2018.

• For the quarter ending Q4 2018, Non-Current Deffered Revenue fell 97.18% year-over-year to $4000.0; the trailing twelve-month figure through Dec 2018 stood at $4000.0 (down 97.18% YoY), and the FY2018 full-year result was $4000.0, down 97.18% from the prior year.
• Non-Current Deffered Revenue for Q4 2018 stood at $4000.0, down from $6000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $49.0 million in Q1 2018, with the low at $4000.0 in Q4 2018.
• Historically, Non-Current Deffered Revenue has averaged $7.1 million across 5 years, with a median of $446500.0 in 2015.
• The largest YoY upside for Non-Current Deffered Revenue was 19436.65% in 2018 against a maximum downside of 99.82% in 2018.
• Alaunos Therapeutics' Non-Current Deffered Revenue stood at $570000.0 in 2014, then surged by 8306.49% to $47.9 million in 2015, then tumbled by 99.74% to $126000.0 in 2016, then increased by 12.7% to $142000.0 in 2017, then tumbled by 97.18% to $4000.0 in 2018.
• The last three Non-Current Deffered Revenue figures came in at $4000.0 (Q4 2018), $6000.0 (Q3 2018), and $68000.0 (Q2 2018), per Business Quant data.